MMP12 serves as an immune cell–related marker of disease status and prognosis in lung squamous cell carcinoma
Wei Zhang,Guo-Sheng Li,Xiang-Yu Gan,Zhi-Guang Huang,Rong-Quan He,Hong Huang,Dong-Ming Li,Yu-Lu Tang,Deng Tang,Wen Zou,Jun Liu,Yi-Wu Dang,Gang Chen,Hua-Fu Zhou,Jin-Liang Kong,Hui-ping Lu
DOI: https://doi.org/10.7717/peerj.15598
IF: 3.061
2023-08-16
PeerJ
Abstract:Background Worldwide, lung squamous cell carcinoma (LUSC) has wreaked havoc on humanity. Matrix metallopeptidase 12 ( MMP12 ) plays an essential role in a variety of cancers. This study aimed to reveal the expression, clinical significance, and potential molecular mechanisms of MMP12 in LUSC. Methods There were 2,738 messenger RNA (mRNA) samples from several multicenter databases used to detect MMP12 expression in LUSC, and 125 tissue samples were validated by immunohistochemistry (IHC) experiments. Receiver operator characteristic (ROC) curves, Kaplan–Meier curves, and univariate and multivariate Cox regression analyses were used to assess the clinical value of MMP12 in LUSC. The potential molecular mechanisms of MMP12 were explored by gene enrichment analysis and immune correlation analysis. Furthermore, single-cell sequencing was used to determine the distribution of MMP12 in multiple tumor microenvironment cells. Results MMP12 was significantly overexpressed at the mRNA level ( p < 0.05, SMD = 3.13, 95% CI [2.51–3.75]), which was verified at the protein level ( p < 0.001) by internal IHC experiments. MMP12 expression could be used to differentiate LUSC samples from normal samples, and overexpression of MMP12 itself implied a worse clinical prognosis and higher levels of immune cell infiltration in LUSC patients. MMP12 was involved in cancer development and progression through two immune-related signaling pathways. The high expression of MMP12 in LUSC might act as an antigen-presenting cell–associated tumor neoantigen and activate the body’s immune response. Conclusions MMP12 expression is upregulated in LUSC and high expression of MMP12 serves as a risk factor for LUSC patients. MMP12 may be involved in cancer development by participating in immune-related signaling pathways and elevating the level of immune cell infiltration.
multidisciplinary sciences